Trials Sponsors Conditions Drugs Pricing

Conditions

Gynecological Disease

Keywords

remimazolampropofolgynecological disease

Outcome Measures

Primary Outcomes (1)

Levels of serum N/OFQ, IL-6, STAT3
perioperatively/periprocedurally

Secondary Outcomes (2)

Heart rate
during the surgery
mean arterial pressure
during the surgery

Study Arms (2)

Remimazolam group

EXPERIMENTAL

Remimazolam was used for anesthesia induction and maintenance

Drug: Remimazolam

Propofol group

ACTIVE COMPARATOR

Anesthesia induction and maintenance were carried out using propofol

Drug: propofol

Interventions

RemimazolamDrug

Remimazolam, sufentanil and rocuronium were used during induction, and remimazolam and refentanil were used during maintenance

Remimazolam group

propofolDrug

Propofol, sufentanil and rocuronium were used during induction, and propofol and remifentanil were used during maintenance

Propofol group

Eligibility Criteria

Age18 Years - 64 Years

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

The patient or their family members sign the informed consent form
Age: 18-64 years old, BMI: 18-30kg/m2

Sponsors & Collaborators

Second Hospital of Shanxi Medical University
Otherlead

MeSH Terms

Conditions

Genital Diseases, Female

Interventions

remimazolamPropofol

Condition Hierarchy (Ancestors)

Female Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

yi Han
Second Hospital of Shanxi Medical University
STUDY DIRECTOR

Central Study Contacts

ran Zhang

CONTACT

17835158352 17835158352@163.com

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: SINGLE
Who Masked: PARTICIPANT
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: professor

Study Record Dates

First Submitted

April 20, 2025

First Posted

May 25, 2025

Study Start

June 1, 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

December 1, 2025

Network Pharmacology Was Applied to Explore the Mechanism of Remimazolam Applied in General Anesthesia for Gynecological Surgeries

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Remimazolam group

Propofol group

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Remimazolam group

Propofol group

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record